Navigation Links
BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
Date:12/11/2007

Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. For further information please visit our website at http://www.biomsmedical.com.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that MBP8298 will continue to demonstrate a satisfactory safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
10. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
11. Phase III Trial Finds Pharmaxis Bronchitol Effective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... TORONTO , March 26, 2015 /PRNewswire/ - SQI ... SQIDF) announced that after dealing with certain matters, including ... of shareholders held on March 26, 2015 (the "Meeting") ... until April 8, 2015 at 11:00 a.m. ( ... Meeting has been changed from that previous disclosed. The ...
(Date:3/26/2015)... BOSTON , March 26, 2015 /PRNewswire/ ... ), a global clinical research organization ... signed a definitive agreement to acquire all ... India ("QSI"), a leading provider of specialized ... refers to the collection, detection, assessment, monitoring, ...
(Date:3/25/2015)... the most attractive in the emerging European region, mainly ... and increasing government investment in healthcare, according to a ... set to grow at twice the pace of the ... reaching an approximate market value of $43-60 billion by ... Cross provides total healthcare solutions that address the evolving ...
(Date:3/25/2015)... March 25, 2015  S&P Capital IQ (MHFI) ... Stock Report coverage on Abattis Bioceuticals Corp . ... ATT): is a specialty biotechnology company with capabilities ... and marketing proprietary ingredients, bio-similar compounds, patented equipment ... North America . The company seeks ...
Breaking Biology Technology:SQI Diagnostics Inc. Announces Adjournment of Meeting 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on Abattis Bioceuticals Corp. in S&P Capital IQ Factual Stock Reports 5
... NICHOLASVILLE, Ky., Feb. 4, 2011 MediVet-America, the ... for animals suffering from osteoarthritis, hip dysplasia, ligament ... first year of business having achieved record advances ... new Adipose-Derived Stem Cell Procedure Kit and equipment, ...
... 4, 2011 SeraCare Life Sciences, Inc. (Nasdaq: ... results before U.S. financial markets open on Friday, February 11, ... A.M. Eastern Time on the same day to review first ... webcast live over the Internet and can be accessed by ...
... Mass. (2/3/2011) -- Boston College has been awarded a ... support a team of university researchers developing a new ... that reveal micro- and macroscopic matter with significantly improved ... would join a new class of microscopes known as ...
Cached Biology Technology:Leading Animal Stem Cell Developer MediVet-America Achieves Significant Business Growth Milestones in First Year 2Boston College receives W.M. Keck Foundation funding for nanoscale optical microscope 2
(Date:3/18/2015)... , March 18, 2015 As ... businesses, new revolutionary smart wallets and apps continue to be ... currently entrenched in the mobile payment industry in focus today ... Holding Ltd. (NYSE: BABA ), Apple Inc. (NASDAQ: ... ) and Facebook Inc. (NASDAQ: FB ) ...
(Date:3/16/2015)... 16, 2015 Between 16 ... present groundbreaking innovations in biometric identification at the ... .      (Photo: http://photos.prnewswire.com/prnh/20150316/735333 ... is well at the forefront: the company,s all ... in Germany . BiometricGate is ...
(Date:3/12/2015)... Calif. , March 12, 2015 WHEN:Tuesday, ... Complimentary Registration here: http://bit.ly/1G7Os0L . SPEAKERS: , ... Aravind SeshagiriPhoto - http://photos.prnewswire.com/prnh/20150311/181111 ... order to compete in several different markets and ... is currently witnessing an uptrend. ...
Breaking Biology News(10 mins):Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 2Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 3Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 4Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 5Revolutionary Smart Wallet & Mobile Payment Choices Change the Game for Consumers - Company Begins Shipping Newest Digital Wallet to Customers 6DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3
... forests of Panama and Costa Rica. A tiny ... nocturnal bee, helping to determine which individuals become queens ... from the University of Washington and the Smithsonian Tropical ... parasite having a positive affect on the social behavior ...
... mike, start the recording, the stage is set for the ... in conjunction with the birdsong archives of Berlin,s Humboldt ... This has nothing to do with entertainment, but a lot ... of voice detector involved can reliably recognise the characteristic birdsong ...
... tularemia, a fatal disease caused by the pathogen Francisella ... warfare agent. Until recently we knew very little about this ... Journal of Medical Microbiology , research on the bacterium has ... how it causes disease. Infection with F. tularensis ...
Cached Biology News:A bee's future as queen or worker may rest with parasitic fly 2Birdsong not just for the birds 2Francisella tularensis: Stopping a biological weapon 2
...
... assay (ELISA) test kits are qualitative one-step ... detection of drugs and/or their metabolites in ... forensic use only. It is recommended that ... quantitative method such as GC/MS. The ...
96 Well Base Plate...
... Inhibitor is a recombinant human protein produced in ... neutral pancreatic RNase A type enzymes. The ... binds RNases in a 1:1 ratio. The enzyme ... many tissues and cell types. Addition of the ...
Biology Products: